Billionaires
-
We don't like breaking things. We like breaking perceptions: Aditya Burman
Youngest Burman on his new role as non-executive additional director at Dabur
-
India's Richest 2019: Asian Paints is a bright picture
Asian Paints' promoters saw their wealth soar to over $1 billion each on the back of buoyant sales
-
India's Richest 2019: Berger Paints' Dhingras score flying colours
With a slow and steady approach, the Dhingras have made Berger Paints India's second-largest paint company
-
India's Richest 2019: Hasmukh Chudgar is pharma's silver lining in tough year
Intas's Hasmukh Chudgar is among the pharma tycoons to have grown their wealth this year
-
India's Richest 2019: What makes Uday Kotak Mr Bankable
Uday Kotak has steered the Kotak Mahindra group successfully through three decades, and some tumultuous times
-
India's Richest 2019: Why Infy founders bucked the trend
Riding on digital services, the IT services bellwether has made some founders richer, but recent whistleblower allegations of corporate governance lapses came as a bolt from the blue
-
India's Richest 2019: Rishad Premji has tough calls to make
In the past five years, Wipro's growth has lagged rivals Infosys and Tata Consultancy Services. Rishad Premji takes over from his father, Azim Premji, at a challenging time
-
India's Richest 2019: Those who slipped and crashed out
With a slowing economy, billionaires who had leveraged to expand their businesses hit a wall. Fifty-two listees saw their rankings fall, while seven fell off the list
-
India's Richest 2019: Adar Poonawalla diversifies into finance
Poonawalla recently set up Poonawalla Finance to provide loans to low- and middle-income consumers as well as to small businesses.
-
India's Richest 2019: Fun facts, figures and factors behind the dollars
The 2019 Forbes India Rich List has six new faces, plus the biggest wealth gainers and losers of the year, in a series of nifty charts
-
India's Richest 2019: Cadila's Patels' quest for the magic pill
The Patels of Cadila are betting big in the high-risk, high-return arena of new drug discovery, but they are hedging it with a presence across the pharma value chain